Breakthrough: rituximab beats standard drug in keeping rare blood vessel disease at bay

This study tested whether rituximab, a targeted immune therapy, is better than azathioprine (a standard drug) at preventing major relapses in people with ANCA-associated vasculitis, a rare autoimmune disease that inflames blood vessels. 117 adults who were already in remission were randomly assigned to receive either rituximab or azathioprine for 18 months, plus 10 months of follow-up. The main goal was to see which group had fewer severe flare-ups. The trial was completed and showed that rituximab was more effective at maintaining remission.